Drug-labels.com

Tobramycin for Injection USP: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Current status: Dormant
Strength:
1.2 g
Active ingredient:
ATC code:

Patient Medication Information: uses, side effects, how to take - Tobramycin for Injection USP

ABOUT THIS MEDICATION

What the medication is used for:

Tobramycin for Injection USP is an antibiotic for intravenous infusion used to treat resistant infections of the respiratory tract, blood, urinary tract and central nervous system, as well as serious skin and soft tissue infections.

Antibacterial drugs like Tobramycin for Injection USP treat only bacterial infections. They do not treat viral infections such as the common cold. Although you may feel better early in treatment, Tobramycin for Injection USP should be used exactly as directed. Misuse or overuse of Tobramycin for Injection USP could lead to the growth of bacteria that will not be killed by Tobramycin for Injection USP (resistance). This means that Tobramycin for Injection USP may not work for you in the future. Do not share your medicine.

What it does:

Tobramycin for Injection USP is believed to interfere with the bacteria’s normal protein synthesis so that it cannot grow or function properly.

When it should be used:

Tobramycin for Injection USP may be indicated for the treatment of the following infections when caused by susceptible organisms: septicemia, complicated and recurrent urinary tract infections, lower respiratory infections, serious skin and soft tissue infections including burns and peritonitis and central nervous system infections caused by organisms resistant to antibiotics usually considered efficacious in these infections.

Tobramycin for Injection USP is usually active against most strains of the following organisms in vitro and in clinical infections:

Pseudomonas aeruginosa

Proteus sp. (Indole-positive and indole- negative),

including Proteus mirabilis,

Morganella morganii,

Providencia rettgeri, and Proteus vulgaris Escherichia coli

Klebsiella-Enterobacter-Serratia group

Citrobacter sp.

Providencia sp.

Staphylococci, including Staphylococcus aureus

(coagulase-positive and coagulase-negative)

When it should not be used:

If you are allergic (hypersensitive) to tobramycin or other aminoglycosides.

What the medical ingredients are:

tobramycin sulphate

IMPORTANT: PLEASE READ

What the important non-medicinal ingredients are:

Sulfuric Acid and/or Sodium Hydroxide may have been added during manufacturing to adjust pH.

What dosage forms it comes in:

Each vial contains tobramycin sulphate equivalent to 1.2 g tobramycin.

WARNINGS AND PRECAUTIONS

Before using Tobramycin for Injection USP, tell your doctor if you (or your child) have or have had:

* Drug allergies

* Hearing or balance problem

* Kidney problems

* Myasthenia gravis (a muscle condition) * Parkinson’s Disease

Tell your doctor if you are pregnant, breastfeeding, are planning to become pregnant.

Your doctor may monitor the level of Tobramycin for Injection USP in your blood through blood tests, especially if you are taking medications.

INTERACTIONS WITH THIS MEDICATION

Tobramycin for Injection USP may interact with other medications. Tell your doctor if you (or your child) are taking any medications, especially the following:

* Aminoglycosides (e.g. amikacin, streptomycin, neomycin, kanamycin, gentamycin, paramomycin) * Amphotericin B

* Anaesthetics

* Cephaloridin

* Cisplatin

* Diuretics (specifically potent diuretics) * Polymyxin B

* Succinylcholine

* Tubocurarine

* Vancomycin

* Viomycin

PROPER USE OF THIS MEDICATION

Tobramycin for Injection USP is for intravenous infusion only.

Usual dose:

The amount of antibiotic you (or your child) will receive will be determined by your healthcare professional. It is dependant upon a number of factors, including your age, weight, type of infection, and any pre-existing medical conditions.

IMPORTANT: PLEASE READ

Serious Warnings and Precautions

Patients treated with Tobramycin for Injection USP or other aminoglycosides should be under close clinical observation because these drugs have an inherent potential for causing ototoxicity and nephrotoxicity.

Tobramycin for Injection USP and other similar aminoglycosides have been known to cause hearing and balance problems (ototoxicity) and kidney problems (nephrotoxicity). Your doctor will observe you carefully for warning signs of these events after giving you Tobramycin for Injection USP.

You may receive Tobramycin for Injection USP several times a day over a period of 7-10 days.

Overdose:

Your healthcare professional is trained to recognize the symptoms of an overdose, and deal with its symptoms.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

You may experience side effects from using Tobramycin for Injection USP including:

* Diarrhea

* Fever

* Headache

* Hives

* Itching or skin irritation

* Nausea

* Rash

* Reaction at the injection site

* Tiredness

* Vomiting

Tell your doctor if you notice any of the above.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY
HAPPEN AND WHAT TO DO ABOUT THEM

Talk with your doctor or

pharmacist

Stop taking drug and call your doctor or pharmacist
Symptom / Effect

Only if

severe

In all cases
Uncommon

-Kidney

problems

(decreased

urination)

-Hearing and balance

problems (loss of hearing,

ringing in the ears, dizziness, loss of balance) -Anemia

(symptoms include

weakness,

exhastion, pale skin)

-Unusual

respiratory difficulties

(difficulty

breathing)

✓

✓

✓

✓

✓

✓

✓

✓

There are also other effects which can occur while you are taking tobramycin. These more rarely include kidney and respiratory difficulties. Nerve problems such as hearing, balance, or dizziness, which you may not have experienced before, can occur when you are being administered the drug or may appear weeks after taking it. It is important that you immediately advise your doctor of such events.

This is not a complete list of side effects. For any unexpected effects while taking Tobramycin for Injection, USP contact your doctor or pharmacist.

HOW TO STORE IT

Tobramycin for Injection USP in powder form should be stored at room temperature (15 - 30 ° C).

Protect from light.

Do not use if the solution is hazy, discoloured, leaking, or contains particulate matter (precipitate)

IMPORTANT: PLEASE READ

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at: http://www.sterimaxinc.com or by contacting the sponsor, SteriMax Inc., at: 1-800-881-3550

Last revised: August 15, 2018

IMPORTANT: PLEASE READ

REPORTING SIDE EFFECTS

You can report any suspected side effects associated with the use of health products to Health Canada by:

  • Visiting the Web page on Adverse Reaction

    Reporting (https://www.canada.ca/en/health-canada/services/drugs-health-

    products/medeffect-canada/adverse-reaction-reporting.html) for information on how to report online, by mail or by fax; or

  • Calling toll-free at 1-866-234-2345

Note: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02285150

Revision date stated in the text: August 15, 2018

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Tobramycin for Injection USP

Rx or OTC
Prescription (Rx)?
DIN 02285150
Schedule(s) PRESCRIPTION
Active ingredient(s) Tobramycin (tobramycin sulfate) 1.2 G
Dosage form(s) Powder For Solution
Route(s) of administration Intravenous
Drug class (WHO ATC)
  1. J Antiinfectives for systemic use
    1. J01 Antibacterials for systemic use
      1. J01G Aminoglycoside antibacterials
        1. J01GB Other aminoglycosides
          1. J01GB01 Tobramycin
Company STERIMAX INC
Current status Dormant
Current status date July 24, 2020

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.